Biochemistry & Physiology: Open Access
ISSN: 2168-9652
Mary, Biochem Physiol 2025, 14:2
Rapid Communication
Open Access

Nanoparticle-Based Drug Delivery Systems: Bridging Biochemistry and Therapeutics

Mary Claire*
Department of Physiology and Biophysics, University of Toronto, Canada

Introduction

Over the past few decades, the field of drug delivery has experienced revolutionary advancements, primarily driven by the emergence of nanoparticle-based systems. These systems, which involve the use of nanoparticles to transport and release therapeutic agents, have shown significant potential in enhancing the efficacy, targeting, and safety of various treatments. Nanoparticle-based drug delivery systems bridge the gap between biochemistry and therapeutics by offering innovative solutions to some of the most challenging problems in modern medicine, including poor bioavailability, side effects, and limited tissue targeting [1].

Nanoparticles, typically ranging in size from 1 to 1000 nanometers, can be engineered to encapsulate drugs, protect them from degradation, and direct them to specific sites within the body. This ability to control drug release, improve pharmacokinetics, and target diseased tissues with precision has made nanoparticle-based drug delivery a promising avenue for treating a range of diseases, including cancer, neurodegenerative disorders, and infectious diseases. In this article, we explore the biochemical principles behind nanoparticle-based drug delivery, the types of nanoparticles used, and the potential therapeutic applications of these systems.

Description

The biochemistry of nanoparticle-based drug delivery

Nanoparticle-based drug delivery systems rely on the fundamental principles of nanochemistry, nanotechnology, and biochemistry to design and optimize the particles used in treatment. The success of these systems lies in their ability to alter the bioavailability, solubility, and pharmacokinetics of drugs. Several biochemical and physicochemical characteristics of nanoparticles, such as size, surface charge, composition, and surface functionalization, play a critical role in determining their interactions with biological systems [2].

Size and surface properties: One of the most important characteristics of nanoparticles in drug delivery is their size. The small size allows nanoparticles to easily navigate through biological barriers, such as the blood-brain barrier (BBB) or the endothelial lining of blood vessels. Particles smaller than 100 nm are particularly effective at reaching target sites and can be more efficiently internalized by cells through processes like endocytosis. Additionally, the surface charge of nanoparticles influences their interactions with biological membranes. For instance, negatively charged nanoparticles tend to interact more effectively with positively charged cell membranes, which can enhance cellular uptake [3].

Surface functionalization: The surface of nanoparticles can be functionalized with various ligands, antibodies, peptides, or other biomolecules that promote targeted delivery to specific cells or tissues. By modifying the nanoparticle surface, drugs can be delivered more precisely to disease sites, such as cancer cells or infected tissues. This targeted approach minimizes the interaction of the drug with healthy cells, thereby reducing side effects and improving therapeutic outcomes.

Encapsulation and drug loading: Nanoparticles can be designed to encapsulate drugs, either in their core or on their surface. The choice of encapsulation method depends on the drug's chemical properties, such as its solubility and stability. For example, hydrophobic drugs are typically encapsulated within the nanoparticle core, whereas hydrophilic drugs can be loaded onto the surface. The release rate of the drug can be controlled by modifying the composition of the nanoparticle or by using stimuli-responsive systems, which release the drug in response to changes in the microenvironment (e.g., pH, temperature, or enzymatic activity) [4].

Biodegradability and biocompatibility: The materials used to construct nanoparticles must be biodegradable and biocompatible to avoid toxicity and accumulation in the body. Biodegradable nanoparticles, such as those made from lipids, polysaccharides, or synthetic polymers, break down into non-toxic byproducts that can be safely excreted. Biocompatibility ensures that the nanoparticles do not elicit harmful immune responses, allowing for their repeated use in therapeutic applications [5].

Types of nanoparticles in drug delivery

There is a wide variety of nanoparticles used in drug delivery, each with unique advantages and limitations. These can be broadly classified into organic and inorganic nanoparticles.

Liposomes: Liposomes are spherical vesicles made from lipid bilayers, mimicking biological cell membranes. These nanoparticles are highly biocompatible and can encapsulate both hydrophilic and hydrophobic drugs. Liposomes can be functionalized with ligands for targeted drug delivery and are particularly effective for delivering chemotherapeutic agents and vaccines [6].

Polymeric nanoparticles: Polymeric nanoparticles are composed of synthetic or natural polymers, such as poly(lactic-co-glycolic acid) (PLGA), chitosan, or polyethylenimine (PEI). These particles are versatile and can be engineered to carry a wide range of drugs, including proteins, peptides, and nucleic acids. Polymeric nanoparticles are often used for sustained or controlled release applications due to their ability

***Corresponding author:** Mary Claire, Department of Physiology and Biophysics, University of Toronto, Canada, E-mail: mclaireuw0u@gmail.com

Received: 05-Mar-2025, Manuscript No: bcp-25-164043, **Editor assigned:** 07-Mar-2025, Pre QC No: bcp-25-164043 (PQ), **Reviewed:** 21-Mar-2025, QC No: bcp-25-164043, **Revised:** 24-Mar-2025, Manuscript No: bcp-25-164043 (R), **Published:** 31-Mar-2025, DOI: 10.4172/2168-9652.1000519

Citation: Mary C (2025) Nanoparticle-Based Drug Delivery Systems: Bridging Biochemistry and Therapeutics. Biochem Physiol 14: 519.

to be tailored for specific drug release profiles [7].

Nanocrystals: Nanocrystals are tiny particles of poorly soluble drugs that are reduced to the nanoscale to increase their surface area and solubility. By increasing the drug's solubility, nanocrystals enhance its bioavailability, making them ideal for oral drug delivery. These nanoparticles are also highly suitable for parenteral formulations, including intravenous injection.

Dendrimers: Dendrimers are highly branched, tree-like polymers that have a uniform size and a high surface area. These nanoparticles can be designed with multiple functional groups on their surface, allowing for efficient drug loading and targeted delivery. Dendrimers are particularly useful for delivering small molecules, proteins, and nucleic acids, and can be engineered to overcome biological barriers [8].

Inorganic nanoparticles: Inorganic nanoparticles, such as gold nanoparticles, silica nanoparticles, and magnetic nanoparticles, have garnered attention for their stability, ease of functionalization, and ability to carry large amounts of drugs. Magnetic nanoparticles, for example, can be guided to specific sites in the body using an external magnetic field, making them valuable for localized drug delivery, especially in cancer therapy.

Therapeutic applications of nanoparticle-based drug delivery

The development of nanoparticle-based drug delivery systems has opened up new possibilities for treating a wide range of diseases, particularly those that have been challenging to manage with traditional drug delivery methods.

Cancer therapy: One of the most promising applications of nanoparticle-based drug delivery is in cancer treatment. Nanoparticles can be designed to specifically target tumor cells, allowing for higher drug concentrations at the site of the tumor while minimizing systemic toxicity. Furthermore, nanoparticles can be loaded with chemotherapy agents, RNA-based therapeutics (such as siRNA), or immunotherapeutic agents to enhance the therapeutic response. For example, liposomal formulations of doxorubicin, such as Doxil, have shown improved efficacy and reduced side effects in patients with ovarian cancer [9].

Gene therapy: Nanoparticles are also being explored for gene delivery, where they serve as carriers for therapeutic genes or nucleic acids. Since nucleic acids (DNA, RNA) are prone to degradation by enzymes in the body, nanoparticles can protect these molecules during transport to target cells. Polymeric nanoparticles and dendrimers are particularly useful in gene therapy applications, as they can efficiently deliver genetic material into cells and promote sustained gene expression.

Neurodegenerative diseases: Nanoparticle-based drug delivery systems are being developed to treat diseases of the central nervous system (CNS), such as Alzheimer's disease and Parkinson's disease. The blood-brain barrier (BBB) is a major obstacle to the effective delivery of drugs to the brain, but nanoparticles can be engineered to cross this barrier. Targeted nanoparticles, functionalized with specific ligands that recognize receptors on brain endothelial cells, can be used to deliver neuroprotective drugs or gene therapies directly to the brain.

Infectious diseases: Nanoparticles are also being used to treat bacterial, viral, and fungal infections. Nanoparticle-based formulations can be engineered to improve the solubility, stability, and release profiles of antimicrobial drugs, making them more effective in combating infections. Additionally, nanoparticles can be designed to target bacterial cells specifically, reducing the risk of side effects associated with traditional antibiotics.

Vaccine delivery: Nanoparticles are being explored as adjuvants and carriers for vaccine delivery. By encapsulating antigens, nanoparticles can improve the stability, immunogenicity, and targeted delivery of vaccines. Nanoparticle-based vaccines are being developed for a range of diseases, including cancer and infectious diseases, and offer the potential for more effective and personalized vaccination strategies [10].

Conclusion

Nanoparticle-based drug delivery systems represent a significant advancement in the field of biochemistry and therapeutics, offering innovative solutions to the challenges associated with traditional drug delivery methods. By leveraging the unique properties of nanoparticles, such as their small size, surface functionalization, and ability to encapsulate drugs, these systems enable more targeted, efficient, and controlled drug delivery. Their applications span a wide range of therapeutic areas, from cancer treatment to gene therapy, neurodegenerative diseases, and infectious diseases. As research continues to advance, nanoparticle-based drug delivery systems hold the promise of revolutionizing the treatment of complex diseases, improving patient outcomes, and minimizing side effects. Ultimately, the integration of nanotechnology into medicine marks a new era in personalized, precision-driven healthcare.

Acknowledgement

None

Conflict of Interest

None

References

1. Aravinthan A (2014) The senescent hepatocyte gene signature in chronic liver disease. Exp Gerontol 60: 37-45.
2. Sebastian C (2009) Telomere shortening and oxidative stress in aged macrophages results in impaired STAT5a phosphorylation. J Immunol 183: 2356-2364.
3. Jun JI, Lau LF (2017) CCN2 induces cellular senescence in fibroblasts. J Cell Commun Signal 11: 15-23.
4. Rodier F (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973-979.
5. Liu D, Xu Y (2011) p53, oxidative stress, and aging. Antioxid Redox Signal 15: 1669-1678.
6. Soto-Gamez A, Demaria M (2017) Therapeutic interventions for aging: the case of cellular senescence. Drug Discov Today 22: 786-795.
7. Kirkland JL (2017) The Clinical Potential of Senolytic Drugs. J Am Geriatr Soc 65: 2297-2301.
8. Cerella C (2016) Roles of Apoptosis and Cellular Senescence in Cancer and Aging. Curr Drug Targets 17: 405-415.
9. Iakovou E, Kourti M (2022) A Comprehensive Overview of the Complex Role of Oxidative Stress in Aging, The Contributing Environmental Stressors and Emerging Antioxidant Therapeutic Interventions. Front Aging Neurosci 14: 827-900.
10. Yan Y (2013) Involvement of reactive oxygen species in a feed-forward mechanism of Na/K-ATPase-mediated signaling transduction. J Biol Chem 288: 34249-34258.